IPF Patients Benefit from Pirfenidone Treatment

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email


An analysis of pooled data from three Phase 3 clinical trials in idiopathic pulmonary fibrosis (IPF) patients shows that treatment with pirfenidone for one year significantly reduced disease progression. The study, titled “Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials,” was published in the European Respiratory Journal.

Pirfenidone (Esbriet, developed by Genentech, Roche) is an oral antifibrotic agent tested as a treatment for IPF in three multinational Phase 3 clinical trials: two CAPACITY trials, investigating pirfenidone’s efficacy and safety as a therapy for at least 72 weeks, and the ASCEND trial, which evaluated treatment with pirfenidone for 52 weeks.

Read more about it: http://bit.ly/1meAarp